U.S. market Closed. Opens in 1 day 5 hours 52 minutes

RDUS | Radius Health, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 15.43 - 16.37
52 Week Range 12.69 - 31.70
Beta 1.60
Implied Volatility 63.25%
IV Rank 40.50%
Day's Volume 670,192
Average Volume 183,490
Shares Outstanding 27,955,300
Market Cap 433,866,256
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
IPO Date 2014-06-06
Valuation
Profitability
Growth
Health
P/E Ratio -1.66
Forward P/E Ratio N/A
EPS -9.37
1YR Price Target N/A
Dividend Yield 4.29%
Dividend Per Share 0.67
Dividend ExDate N/A
Dividend PayDate N/A
Employees 3,011
Country USA
Website RDUS
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.
RDUS's peers: FMTX, EWTX, EIGR, LIAN, ZYXI, CERC, AADI, TALS, PHAT, FLDM
*Chart delayed
Analyzing fundamentals for RDUS we got that it has average fundamentals where Valuation is considered to be slightly undervalued, Profitability is unacceptably poor, Growth is exceptionally good and Health is weak. For more detailed analysis please see RDUS Fundamentals page.

Watching at RDUS technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on RDUS Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙